http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_36e8adfea214dd7ede35d45c62b65bd1
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Kage |
| name | Masayoshi Kage |
| given-name | Masayoshi |
| organization-name | Working Group and Association of Pathologists for Guidebook of NASH and NAFLD, 2015: The Japan Society of Hepatology Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan; Research Center for Innovate Cancer Therapy Kurume University Kurume Japan Authors' Affiliations: 1Department of Pharmaceutical Oncology and 2Laboratory of Molecular Cancer Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka; 3Department of Diagnostic Pathology, Kurume University Hospital, Kurume; 4Section of Functional Morphology, Faculty of Pharmaceutical Science, Nagasaki International University, Nagasaki; 5Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; 6St. Mary's Institute of Health Science, St. Mary's Hospital, Kurume, Japan; and 7Pangaea Biotech, Dexeus University Institute, Barcelona, Spain Department of Diagnostic Pathology, Kurume University Hospital, Kurume 830-0011, Japan Department of Pathology, Kurume University School of Medicine, Kurume,4 Japan Research Center for Innovative Cancer Therapy Kurume University Kurume Japan Center for Innovative Cancer Therapy, Kurume University Research, Kurume 2Pathology, Molecular Targeting Therapeutics Division, Research Center for Innovative Cancer Therapy Kurume University Fukuoka Japan Research Center for Innovative Cancer Therapy Kurume University School of Medicine Kurume Japan; Department of Diagnostic Pathology Kurume University Hospital Kurume Japan Authors' Affiliations: 1Department of Pharmaceutical Oncology, 2Laboratory of Molecular Cancer Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka; 3St. Mary's Hospital, Kurume; 4Department of Diagnostic Pathology, Kurume University Hospital, and 5Biostatistics Center, Kurume University, Kurume, Japan 3Research Center for Innovative Cancer Therapy, Kurume University;; 4Department of Pathology, Kurume University Hospital; Authors' Affiliations: 1Department of Diagnostic Pathology, Kurume University Hospital; 2Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine; 3Biostatistics Center, Kurume University, Kurume, Japan; 4Department of Pharmaceutical Oncology; 5Laboratory of Molecular Cancer Biology, Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan; and 6Department of Thoracic Surgery, Aichi Cancer Center Research Institute, Nagoya, Japan Kurume University Research Center for Innovative Cancer Therapy,Kurume,Japan Department of Pathology, Kurume University School of Medicine, Japan Research Center for Innovative Cancer Therapy Kurume University School of Medicine Kurume Japan; Cancer Center Kurume University Hospital Kurume Japan; Department of Diagnostic Pathology Kurume University Hospital Kurume Japan 3Pathology, Kurume University, Kurume, Japan and Kurume University Research Center for Innovative Cancer Therapy Fukuoka Japan Department of Diagnostic Pathology, Kurume University Hospital Kurume University Research Center for Innovative Cancer Therapy Kurume Japan Cancer Center Kurume University Hospital Kurume Fukuoka Japan; Department of Diagnostic Pathology Kurume University Hospital Kurume Fukuoka Japan Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan. Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Fukuoka, Japan Kurume University Research Center for Innovative Cancer Therapy,Fukuoka,Japan 1Center for Innovative Cancer Therapy of the 21st Century Center of Excellence Program for Medical Science;; 4Department of Pathology, Kurume University Hospital, Kurume, Japan; Department of Diagnostic Pathology Kurume University Hospital Kurume Japan Cancer Center Fukuoka Japan; Department of Diagnostic Pathology Kurume University Hospital Fukuoka Japan First Department of Pathology Kurume University School of Medicine Kurume First Department of Pathology, Kurume University School of Medicine. Kurume, Japan. First Department of Pathology, Kurume University School of Medicine, Kurume, Japan; Department of Pathology Kurume University School of Medicine Kurume Japan Department of Pathology, Kurume University, Fukuoka, Japan. 3Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan. Kurume University Research Center for Innovative Cancer therapy,Fukuoka,Japan 3Department of Diagnostic Pathology, Kurume University Hospital, Fukuoka, Japan. Department of Diagnostic Pathology Kurume University Hospital Fukuoka Japan Authors' Affiliations: 1Research Center for Innovative Cancer Therapy, Kurume University; 2Department of Surgery, Kurume University School of Medicine; 3Dental and Oral Medicine Center and 4Department of Pathology, Kurume University Hospital, Kurume, Japan; 5National Hospital Organization Kyushu Medical Center, Fukuoka, Japan; and 6Laboratory of Experimental Immunology, Cancer and Inflammation Program, Science Applications International Corporation–Frederick, Inc., National Cancer Institute–Frederick, Frederick, Maryland; Authors' Affiliations: 1Research Center for Innovative Cancer Therapy, Kurume University; 2Department of Surgery, Kurume University School of Medicine; 3Dental and Oral Medicine Center and 4Department of Pathology, Kurume University Hospital, Kurume, Japan; 5National Hospital Organization Kyushu Medical Center, Fukuoka, Japan; and 6Laboratory of Experimental Immunology, Cancer and Inflammation Program, Science Applications International Corporation–Frederick, Inc., National Cancer Institute–Frederick, Frederick, Maryland 5Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.; 8Research Center of Innovative Cancer Therapy, Kurume University, Kurume, Japan. Department of Diagnostic Pathology Kurume University Hospital Kurume Fukuoka Japan Authors' Affiliations: 1Department of Pharmaceutical Oncology and 2Laboratory of Molecular Cancer Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan; 3Department of Pathology and 4Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan; and 5Department of Molecular Biology and 6Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan; Authors' Affiliations: 1Department of Pharmaceutical Oncology and 2Laboratory of Molecular Cancer Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan; 3Department of Pathology and 4Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan; and 5Department of Molecular Biology and 6Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan Department of Diagnostic Pathology Kurume University Hospital Kurume, Fukuoka Japan Department of Medical Engineering Junshin Gakuen University Fukuoka Japan Department of Pathology Kurume University Hospital Kurume Japan |
Incoming Links
Total number of triples: 300.